Vamsidhar Velcheti, MD

home / authors / vamsidhar-velcheti-md

Articles

Cancer Network Faceoff: Conclusion of the Event and Presentation of Awards

Cancer Network Faceoff: Conclusion of the Event and Presentation of Awards

Deborah Doroshow, MD;Neel Chudgar, MD;Vamsidhar Velcheti, MD;Daniel R. Gomez, MD;Jamie E Chaft, MD;Fred R. Hirsch, MD, PhD;Mark G. Kris, MD
December 28th 2023

Conclusion of the discussion and award presentation.

Optimal Approach for PD-L1 >50%

Optimal Approach for PD-L1 >50%

Deborah Doroshow, MD;Neel Chudgar, MD;Vamsidhar Velcheti, MD;Daniel R. Gomez, MD;Jamie E Chaft, MD;Fred R. Hirsch, MD, PhD;Mark G. Kris, MD
December 21st 2023

Discussion regarding immunotherapy alone or in combination with chemotherapy for patients with NSCLC that are PD-L1 >50%.

Treatment for Borderline Resectable Patients With NSCLC

Treatment for Borderline Resectable Patients With NSCLC

Deborah Doroshow, MD;Neel Chudgar, MD;Vamsidhar Velcheti, MD;Daniel R. Gomez, MD;Jamie E Chaft, MD;Fred R. Hirsch, MD, PhD;Mark G. Kris, MD
December 21st 2023

Discussion on the treatment for borderline resectable patients with NSCLC.

Will Combination Therapies Replace Osimertinib Monotherapy as Standard-of-Care in Frontline EGFR-Mutant Advanced NSCLC?

Will Combination Therapies Replace Osimertinib Monotherapy as Standard-of-Care in Frontline EGFR-Mutant Advanced NSCLC?

Deborah Doroshow, MD;Neel Chudgar, MD;Vamsidhar Velcheti, MD;Daniel R. Gomez, MD;Jamie E Chaft, MD;Fred R. Hirsch, MD, PhD;Mark G. Kris, MD
December 14th 2023

Osimertinib monotherapy as the standard of treatment for frontline EGFR mutant advanced NSCLC will be replaced by combination therapies.

Adjuvant Osimertinib for Resected EGFR Mutated Stage IB-IIIA Non-Small Cell Lung Cancer

Adjuvant Osimertinib for Resected EGFR Mutated Stage IB-IIIA Non-Small Cell Lung Cancer

Deborah Doroshow, MD;Neel Chudgar, MD;Vamsidhar Velcheti, MD;Daniel R. Gomez, MD;Jamie E Chaft, MD;Fred R. Hirsch, MD, PhD;Mark G. Kris, MD
December 14th 2023

EGFR-mutated stage IB-IIIA non-small cell lung carcinoma that has been removed and treated with adjuvant osimertinib.

Brigatinib Versus Crizotinib in ALK inhibitor-Naïve Advanced ALK-Positive NSCLC: Results of Phase 3 ALTA-1L Trial

Brigatinib Versus Crizotinib in ALK inhibitor-Naïve Advanced ALK-Positive NSCLC: Results of Phase 3 ALTA-1L Trial

Deborah Doroshow, MD;Neel Chudgar, MD;Vamsidhar Velcheti, MD;Daniel R. Gomez, MD;Jamie E Chaft, MD;Fred R. Hirsch, MD, PhD;Mark G. Kris, MD
December 7th 2023

Results of phase 3 ALTA-1L study comparing crizotinib with Brigatinib in advanced ALK-positive non-small cell lung cancer

Introduction of the Debate Between Jets v. Giants

Introduction of the Debate Between Jets v. Giants

Deborah Doroshow, MD;Neel Chudgar, MD;Vamsidhar Velcheti, MD;Daniel R. Gomez, MD;Jamie E Chaft, MD;Fred R. Hirsch, MD, PhD;Mark G. Kris, MD
December 7th 2023

An outline of the debate, the speakers, and the basic guidelines to support the program.

Tools, Biomarkers Needed to Identify Immune-Related Toxicities

Tools, Biomarkers Needed to Identify Immune-Related Toxicities

Vamsidhar Velcheti, MD
September 6th 2017

This video reviews the need for biomarkers and tools that could identify those at high risk of immune-related toxicities among patients undergoing immunotherapy treatment.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes
Published: August 26th 2011 | Updated: July 7th 2025
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes